Skip to main content

Table 3 Association of the N363S (p = 0.878), BCLI (p = 0.343), ER2223EK (p = 0.966) and disease severity.

From: Glucocorticoid receptor gene polymorphisms and potential association to chronic obstructive pulmonary disease susceptibility and severity

GOLD   Wild-type Heterozygote Homozygote
N363S Polymorphism- n (%)
Chronic bronchitis 23 21 (91.3) 2 (8.7) 0 (0.0)
GOLD I 8 7 (87.5) 1 (12.5) 0 (0.0)
GOLD II 66 58 (87.9) 8 (12.1) 0 (0.0)
GOLD III 50 45 (90.0) 5 (10.0) 0 (0.0)
GOLD IV 60 54 (90.0) 6 (10.0) 0 (0.0)
BCLI Polymorphism- n (%)
chronic bronchitis 23 9 (39.1) 11 (47.8) 3 (13.0)
GOLD I 8 1 (12.5) 5 (62.5) 2 (25.1)
GOLD II 66 24 (36.4) 31 (47.0) 11 (16.7)
GOLD III 50 21 (42.0) 20 (40.0) 9 (18.0)
GOLD IV 60 28 (46.7) 25 (41.7) 7 (11.7)
ER2223EK Polymorphism- n (%)
chronic bronchitis 23 23 (100) 0 (0.0) 0 (0.0)
GOLD I 8 7 (87.5) 1 (12.5) 0 (0.0)
GOLD II 66 63 (95.5) 3 (4.6) 0 (0.0)
GOLD III 50 47 (94.0) 3 (6.0) 0 (0.0)
GOLD IV 60 58 (96.7) 2 (3.3) 0 (0.0)
  1. No significant differences were observed between GOLD stages and those single nucleotide polymormphisms (SNPs).